Bristol Myers Squibb Receives FDA Approval for ZENBEXUS in Multiple Myeloma Treatment
Product·3 articles across 3 outlets·◆ Primary source·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma as early as first relapse.
This approval marks a significant milestone for Bristol Myers Squibb, as it is the first for a group of protein-degrading CELMoD therapies, expanding treatment options for advanced multiple myeloma patients.
Bristol Myers SquibbZENBEXUSFDA
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluroni…”
SEC Filing — U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluroni…“<figure><div><img”
biopharma dive — Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene“The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.”
stat news — STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
Earlier versions
- Aug 14, 4:02 PM — Bristol Myers Wins FDA Approval for Zenbexus, First in New Myeloma Drug Class (2/2)